- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05836259
Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM (MyPEAK-1)
January 19, 2024 updated by: Tenaya Therapeutics
First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adenoassociated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-Associated Hypertrophic Cardiomyopathy (HCM)
This is a first-in-human, non-randomized, open-label study designed to evaluate the safety, tolerability, and pharmacodynamics (PD) of TN-201 in adult patients with symptomatic MYBPC3 mutation-associated nonobstructive hypertrophic cardiomyopathy (nHCM).
Study Overview
Detailed Description
The study will consist of 2 escalating dose cohorts.
The study will enroll at least 6 and as many as 15 patients.
All patients will receive active drug.
The study will follow patients for 5 years following a single dose of TN-201.
Study Type
Interventional
Enrollment (Estimated)
15
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Laura Robertson, M.D.
- Phone Number: 650-416-1186
- Email: lrobertson@tenayathera.com
Study Contact Backup
- Name: LaTanya Tomlinson, RN, MHSA
- Phone Number: 650-825-6990
- Email: clinical.trials@tenayathera.com
Study Locations
-
-
California
-
La Jolla, California, United States, 92093
- Not yet recruiting
- UC San Diego Altman Clinical and Translational Research Institute - Center for Clinical Research
-
San Francisco, California, United States, 94117
- Recruiting
- University of California San Francisco
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Not yet recruiting
- Emory University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Not yet recruiting
- Brigham and Women's Hospital
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Not yet recruiting
- University of Cincinnati Health Physicians - Clifton
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Not yet recruiting
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Not yet recruiting
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Not yet recruiting
- University of Pittsburgh Medical Center
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- Houston Methodist Hospital
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Not yet recruiting
- University Of Utah
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- MYBPC3 mutation
- Nonobstructive Hypertrophic Cardiomyopathy
- Left Ventricular Ejection Fraction ≥50%
- Functioning Implantable Cardiac Defibrillator
- NYHA Functional Class II or III symptoms
- NT-proBNP ≥300pg/ml
Exclusion Criteria:
- High AAV9 neutralizing antibody titer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
Dose for Cohort 1 will be 3E13 vg/kg
|
TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene.
It is a single (one-time) intravenous dose.
|
Experimental: Cohort 2
Dose for Cohort 2 will be 6E13 vg/kg
|
TN-201 is a recombinant adeno-associated virus serotype 9 (AAV9) containing Myosin Binding Protein C (MYBPC3) transgene.
It is a single (one-time) intravenous dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number and severity of Adverse Events over the course of the study.
Time Frame: 5 Years
|
5 Years
|
Number of Serious Adverse Events related to study drug.
Time Frame: 5 Years
|
5 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline to Week 52 in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS).
Time Frame: 52 Weeks
|
The score ranges from 0-100, with zero being a worse outcome
|
52 Weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Expression levels of vector genomes and transgene messenger ribonucleic acid (mRNA) and MyBP-C protein in right ventricular (RV) septal biopsy samples at Week 8 and Week 52.
Time Frame: 52 Weeks
|
52 Weeks
|
Change from Pre-dose in N-terminal pro B-type natriuretic peptide (NTproBNP), and high-sensitivity cardiac troponin I (hs-cTnI) levels.
Time Frame: 5 Years
|
5 Years
|
Change from baseline peak exercise capacity (pVO2).
Time Frame: 5 Years
|
5 Years
|
Percentage of patients who had a change in New York Heart Association (NYHA) Functional Class from baseline.
Time Frame: 5 Years
|
5 Years
|
Change from baseline in echocardiography measurement of left ventricular mass index (g/m^2).
Time Frame: 5 Years
|
5 Years
|
Change from baseline in echocardiography measurement of e/e' ratio.
Time Frame: 5 Years
|
5 Years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 10, 2023
Primary Completion (Estimated)
December 1, 2025
Study Completion (Estimated)
December 1, 2029
Study Registration Dates
First Submitted
April 18, 2023
First Submitted That Met QC Criteria
April 18, 2023
First Posted (Actual)
May 1, 2023
Study Record Updates
Last Update Posted (Estimated)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 19, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TN-201-0009
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertrophic Cardiomyopathy
-
French Cardiology SocietyCompleted1- Primary (Sarcomeric) Hypertrophic Cardiomyopathy | 2- Obstructive Hypertrophic Cardiomyopathy | 3- Non Obstructive Hypertrophic CardiomyopathyFrance
-
Montreal Heart InstituteCanadian Institutes of Health Research (CIHR)Enrolling by invitationCardiomyopathies | Hypertrophic Cardiomyopathy | Hypertrophic Obstructive Cardiomyopathy | Familial Hypertrophic CardiomyopathyCanada
-
University of Sao PauloCompletedNon-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyBrazil
-
Bristol-Myers SquibbActive, not recruitingHypertrophic Cardiomyopathy | Non-obstructive Hypertrophic Cardiomyopathy | Obstructive Hypertrophic CardiomyopathyDenmark, United States, Belgium, Czechia, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
-
Yonsei UniversityCompletedFamilial Hypertrophic CardiomyopathyKorea, Republic of
-
Hangzhou Valgen Medtech Co., LtdNot yet recruitingObstructive Hypertrophic CardiomyopathyChina
-
China National Center for Cardiovascular DiseasesNot yet recruitingObstructive Hypertrophic Cardiomyopathy
-
Bristol-Myers SquibbNot yet recruitingObstructive Hypertrophic CardiomyopathyKorea, Republic of
-
Ji Xing Pharmaceuticals (Shanghai) Co., Ltd.RecruitingObstructive Hypertrophic CardiomyopathyChina
-
Xiang WeiRecruitingNonobstructive Hypertrophic CardiomyopathyChina
Clinical Trials on TN-201
-
Tenaya TherapeuticsJohns Hopkins University; Mayo ClinicRecruitingArrhythmogenic Right Ventricular CardiomyopathyUnited States
-
Hamilton Health Sciences CorporationMcMaster UniversityCompleted
-
[Redacted]Dentsply Sirona Inc.Withheld
-
Chicago Anesthesia Pain SpecialistsCompleted
-
RevBioNot yet recruitingCraniotomyUnited States
-
QurAlis CorporationRecruitingAmyotrophic Lateral SclerosisCanada, Germany, Netherlands, Ireland, United Kingdom, Belgium
-
McGill University Health Centre/Research Institute...Centre de Recherche du Centre Hospitalier de l'Université de Montréal; CIHR... and other collaboratorsTerminated
-
TWi Biotechnology, Inc.CompletedType 2 Diabetes MellitusUnited States, Taiwan
-
Modulation Therapeutics, Inc.H. Lee Moffitt Cancer Center and Research InstituteRecruitingUveal Melanoma | MetastaticUnited States
-
Royal Prince Alfred Hospital, Sydney, AustraliaCompleted